Open Access Repository

Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome

Downloads

Downloads per month over past year

Ding, C 2006 , 'Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome' , Current Opinion in Investigational Drugs, vol. 7, no. 11 , pp. 1020-1025 .

[img]
Preview
PDF
vx-702.pdf | Download (221kB)
Available under University of Tasmania Standard License.

| Preview

Abstract

Vertex Pharmaceuticals Inc, in collaboration with Kissei
Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.

Item Type: Article
Authors/Creators:Ding, C
Journal or Publication Title: Current Opinion in Investigational Drugs
ISSN: 1472-4472
Additional Information:

restricted - published by Thompson

Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP